These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32424601)

  • 1. L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism.
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD
    Neurochem Res; 2020 Jun; 45(6):1438-1450. PubMed ID: 32424601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency].
    Sikorska H; Cianciara J; Wiercińska-Drapało A
    Pol Merkur Lekarski; 2010 Jun; 28(168):490-5. PubMed ID: 20642112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
    Vogels BA; Karlsen OT; Mass MA; Boveé WM; Chamuleau RA
    J Hepatol; 1997 Jan; 26(1):174-82. PubMed ID: 9148009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
    Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
    Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. l-Ornithine-l-Aspartate (LOLA) Normalizes Metabolic Parameters in Models of Steatosis, Insulin Resistance and Metabolic Syndrome.
    Canbay A; Götze O; Kucukoglu O; Weinert S; Croner RS; Baars T; Özçürümez MK; Gieseler RK
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis.
    Horvath A; Traub J; Aliwa B; Bourgeois B; Madl T; Stadlbauer V
    Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Butterworth RF; Canbay A
    Dig Dis; 2019; 37(1):63-68. PubMed ID: 30016770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson's Disease Models.
    Sisalli MJ; Della Notte S; Secondo A; Ventra C; Annunziato L; Scorziello A
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
    Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate.
    Albrecht J; Hilgier W; Januszewski S; Quack G
    Metab Brain Dis; 1996 Sep; 11(3):229-37. PubMed ID: 8869943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction to: L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism.
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD
    Neurochem Res; 2020 Oct; 45(10):2527. PubMed ID: 32638216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
    Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
    Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
    Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
    Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of L-ornithine L-aspartate granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase].
    Yan Z; Wang Y; Mao Q; Wang X; Zhang X; Wang Y; Jiang Y; Xiang DD; Jiang L; Wang J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jul; 22(7):525-8. PubMed ID: 25203805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.